CLAIMS

1) Spherical agglomerates of telithromycin.

2) Spherical agglomerates of telithromycin according to claim 1, characterized in that the size of the particles is between 30 and 400 microns.

3) Spherical agglomerates of telithromycin according to claim 2, characterized in that the median size of the particles is situated between 80 and 150 microns.

Sub A2

4) Spherical agglomerates of telithromycin according to any one of claims 1 to 3, characterized in that the median size of the particles is situated towards 100 microns.

5) Process for the preparation of agglomerates according to any one of claims 1 to 4, characterized in that a suspension of telithromycin crystals is prepared, and these crystals are then coated with a phase insoluble in telithromycin which progressively crystallizes.

6) Preparation process according to claim 5, characterized in that a solution of telithromycin in acetone is used.

7) Preparation process according to claim 5 or 6, characterized in that the crystallization takes place in an acetone/isopropyl ether mixture.

8) Preparation process according to any one of claims 5 to 7, characterized in that the crystallization is carried out between -5°C and -15°C.

9) Spherical agglomerates of telithromycin as obtained by the process according to any one of claims 5 to 8.

10) Spherical agglomerates of telithromycin according to claim 9, characterized in that the particle size is comprised between 30 and 400 microns.

11) Spherical agglomerates of telithromycin according to claim 10, characterized in that the median size of the particles is situated between 80 and 150 microns.

AMENDED PAGE

12) Spherical agglomerates of telithromycin according to any one of claims 9 to 11, characterized in that the median size of the particles is situated towards 100 microns.

13) Use of the spherical agglomerates according to any one of claims 1 to 4 and 9 to 12, characterized in that the spherical agglomerates are surrounded by a layer of polymer in order to obtain the sought galenical form.

Add A3